ORYZF (Oryzon Genomics) Net Income (Continuing Operations): $-2.37 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORYZF Oryzon Genomics SA ORYZF
33 GF Score
Price $3.50
View Full Analysis

What is Oryzon Genomics Net Income (Continuing Operations)?

Oryzon Genomics ORYZF +1.45% 33 Net Income (Continuing Operations) is $-2.37 Mil as of Jun. 2026. GuruFocus rates ORYZF with a GF Score™ of 33/100.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Oryzon Genomics's Net Income (Continuing Operations) for the three months ended in Jun. 2026 was $-0.16 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 was $-2.37 Mil.

Oryzon Genomics  (OTCPK:ORYZF) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Oryzon Genomics Net Income (Continuing Operations) Related Terms

Oryzon Genomics Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Oryzon Genomics's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oryzon Genomics Net Income (Continuing Operations) Chart

Oryzon Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.30 -4.48 -3.66 -3.75 -3.05

Oryzon Genomics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.40 -1.18 -1.42 -0.16
ORYZF
33GF Score
Oryzon Genomics SA ORYZF
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oryzon Genomics Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of $-2.37 Mil mean?
Oryzon Genomics (ORYZF) has a Net Income (Continuing Operations) of $-2.37 Mil as of Jun. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Oryzon Genomics and its competitors.
Is Oryzon Genomics' Net Income (Continuing Operations) too high?
Oryzon Genomics' current Net Income (Continuing Operations) is $-2.37 Mil. Overall, Oryzon Genomics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' Net Income (Continuing Operations) compare to VRTX and REGN?
Oryzon Genomics' Net Income (Continuing Operations) of $-2.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Biotechnology company?
A good Net Income (Continuing Operations) depends on the Biotechnology industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Oryzon Genomics and its competitors. Oryzon Genomics's current Net Income (Continuing Operations) is $-2.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (ORYZF) has a current Net Income (Continuing Operations) of $-2.37 Mil. The current Net Income (Continuing Operations) is $-2.37 Mil. Oryzon Genomics' overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Oryzon Genomics (ORYZF), the current Net Income (Continuing Operations) is $-2.37 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oryzon Genomics Business Description

Other Exchanges 0RDB:UKORY:SpainORN:Germany
Address Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
33GF Score

Get the complete analysis for ORYZF

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.50
Price